IFNG and neoplasm: Tumours derived from all three cell lines without chronic IFNγ pre-treatment demonstrated delayed growth in response to α-PD-1 therapy for at least one-week post-treatment before mice eventually succumbed to progressive tumour growth, with tumours derived from YUMM2.1 responding best, followed by CT26 and then MC38 (Fig. 1E–G).